Incyte Corp (NASDAQ:INCY)

54.20
Data as of Aug 29
 +0.26 / +0.48%
Today’s Change
33.01
Today|||52-Week Range
70.86
+7.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$9.1B

Company Description

Incyte Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The company's product, Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. Incyte was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
Experimental Station
Wilmington Delaware 19880
P:(302) 498-6700
Investor Relations:
(302) 498-6944

Employees

Shareholders

Mutual fund holders62.75%
Other institutional35.34%
Individual stakeholders12.75%

Top Executives

Hervé HoppenotPresident, Chief Executive Officer & Director
David C. HastingsChief Financial Officer & Executive Vice President
Richard S. LevyEVP, Chief Drug Development & Medical Officer
Eric H. SiegelSecretary, Executive VP & General Counsel
James M. DalyChief Commercial Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.